AbbVie shares tumble after schizophrenia drug disappoints
US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms
Read more at Financial Times
-
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Business - MarketWatch - November 11 -
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
Business - MarketWatch - November 12 -
Target shares tumble as retailer’s holiday forecast disappoints
World - Financial Times - 23 hours ago -
Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales
Business - Financial Times - October 30 -
Electrolux Shares Tumble After North America Weakness Weighs on Results
Business - The Wall Street Journal - October 25 -
Schroders shares tumble to lowest in over 10 years after warning on outflows
Business - Financial Times - November 5 -
Schroders shares tumble after fund manager reports outflows
Business - MarketWatch - November 5 -
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Health - ABC News - October 31
More from Financial Times
-
Russia fires intercontinental ballistic missile at Ukraine for first time, Kyiv says
Business - Financial Times - 50 minutes ago -
Ukraine fires British Storm Shadow missiles into Russia
Business - Financial Times - 19 hours ago -
Thrive Capital: the venture firm staking billions on a few big bets
Business - Financial Times - 6 hours ago -
Bitcoin tops $98,000 in fresh high
Business - Financial Times - 6 hours ago -
Former UK deputy prime minister John Prescott dies at 86
Business - Financial Times - 4 hours ago